You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatment

    SBC: LONGEVICA PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Eukaryotic elongation factor protein kinase eEF K is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an andquot atypicalandquot kinase domain Our recent findings demonstrate that inhibition or genetic inactivation of eEF K protects normal tissues from cytotoxic effects of ionizing radiation and chemotherapeutic ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION provided by applicant Cognition Therapeutics Inc andapos s mission is to develop effective therapeutics for Alzheimerandapos s disease AD Recent scientific discoveries have identified oligomers of the brain protein A as toxic culprits in disease progression Cognition in partnership with Temple University has identified a novel series of sigma receptor binding modulators t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: R

    DESCRIPTION provided by applicant The ultimate goal of this project is to produce a broad spectrum drug for the treatment of viral infections caused by filoviruses Ebola and Marburg arenaviruses Lassa fever and rhabdoviruses rabies We and others have determined that efficient budding of these emerging human pathogens is dependent on the subversion of host proteins such as Nedd and t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and Ligands

    SBC: MATERIA, INC.            Topic: 300

    DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Enhanced multiphoton microscopy through spatial light modulation

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: 102

    DESCRIPTION provided by applicant Nonlinear optical microscopy techniques and particularly multiphoton fluorescence microscopy have become popular tools for visualizing the three dimensional cellular architecture residing hundreds of microns and up to one millimeter deep in living organisms This is particularly valuable in neurobiology where multiphoton techniques have become widely used fo ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government